Nunziante Magrone advised Herbolea Biotech s.r.l. in the transaction.
The KD Pharma Group SA, a global pharmaceutical CMO and one of the leading producers of Omega-3 fatty acids, and Herbolea Biotech Srl, an Italian biotechnology company developing proprietary botanical extraction technologies, have signed a Licensing Agreement granting KD Pharma the rights to utilize Herbolea’s Bio-Herbolysis™ extraction technology in Europe.
Bio-Herbolysis™ is a highly scalable, solvent-less and environmentally friendly technology that can extract cannabis’ full phytocomplex starting from wet or dry material, yielding 90%+ extraction efficiency while preserving its original acidic forms and terpene profile.
KD Pharma has the largest isolation and fractionation technology portfolio in the lipids industry and with this agreement will expand its capacity for manufacturing a full spectrum of cannabis and terpene-based products for use in pharmaceutical, dietary supplement and medicinal food products.
As part of the agreement, Herbolea commits to deliver Good Manufacturing Practices (GMP) compliant equipment to KD Pharma’s facilities, with the capability to process 100 kg of dry flower or its wet equivalent per batch.
With the signing of this agreement, both parties will start a collaboration for the research and development of post-processing technologies to improve production of cannabis and terpene-based products.
Nunziante Magrone advised Herbolea Biotech s.r.l. in the transaction with a team led by partner Vieri Paoletti (Picture).
Involved fees earner: Vieri Paoletti – Nunziante Magrone;
Law Firms: Nunziante Magrone;
Clients: Herbolea Biotech S.r.l.;